Compare CTRN & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTRN | CABA |
|---|---|---|
| Founded | 1946 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 460.5M | 495.7M |
| IPO Year | 2005 | 2019 |
| Metric | CTRN | CABA |
|---|---|---|
| Price | $57.45 | $2.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $52.00 | $14.50 |
| AVG Volume (30 Days) | 247.6K | ★ 6.5M |
| Earning Date | 06-02-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 112.14 | 10.26 |
| EPS | ★ 0.91 | N/A |
| Revenue | ★ $819,962,000.00 | N/A |
| Revenue This Year | $8.81 | N/A |
| Revenue Next Year | $8.35 | N/A |
| P/E Ratio | $63.40 | ★ N/A |
| Revenue Growth | ★ 8.88 | N/A |
| 52 Week Low | $28.45 | $1.26 |
| 52 Week High | $66.38 | $4.23 |
| Indicator | CTRN | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 57.18 | 43.49 |
| Support Level | $42.10 | $2.77 |
| Resistance Level | $66.38 | $3.42 |
| Average True Range (ATR) | 3.44 | 0.24 |
| MACD | -0.48 | 0.02 |
| Stochastic Oscillator | 32.50 | 31.94 |
Citi Trends Inc is a differentiated off-price value retailer known for trendy fashions, great brands and amazing prices. It is the off-price retailer specifically focused on Black customers, delivering the styles, brands, and trends at amazing prices that resonate with its primary and secondary customers. Its product offering is Women's, Men's and Children's apparel, family footwear, accessories and products for the home, with a three-tiered mix of product. At the opening price point, the company offers value-focused basics for its budget-conscious customers.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.